Statins Cut Dementia Risk in Type 2 Diabetes
Analysis based on 27 articles · First reported Aug 30, 2026 · Last updated Sep 18, 2026
The study could support broader and earlier statin prescribing for type 2 diabetes patients, a modest positive for generic statin makers and healthcare systems facing rising dementia costs. However, because the evidence is observational and statins are inexpensive generics, the near-term revenue impact for pharmaceutical companies is likely limited.
A large observational study presented at the European Society of Endocrinology Congress 2026 in Munich and published in The Lancet Regional Health - Europe found that starting statin therapy soon after a type 2 diabetes diagnosis was associated with a lower risk of developing dementia. Researchers from Rigshospitalet used Danish national registers to track 132,585 people who developed type 2 diabetes between 2006 and 2019 and had no prior statin use, following them through the end of 2021. During a median follow-up of 7.1 years, 2.7% of participants developed dementia. Compared with no statin treatment, early initiation within one year of diagnosis was associated with a 15% lower relative risk of dementia over 10 years, while later initiation between one and five years was associated with a 10% lower risk. Presenter Tummas Ternhamar said the findings suggest another reason to ensure timely statin treatment for type 2 diabetes patients with high LDL cholesterol. Isabel Goncalves of the European Society of Endocrinology Communication Committee welcomed the results, noting statins are widely available and inexpensive, but cautioned the observational design cannot prove statins prevent dementia. Commentators including Bryan Williams of the British Heart Foundation, Honorine Lebraud of Alzheimer s Research UK, Richard Oakley of Alzheimer s Society, and Liron Sinvani of Northwell Health said the study adds to evidence linking cardiovascular and brain health while calling for further research. The work was supported by grants from the Danish Cardiovascular Academy, funded by the Novo Nordisk Foundation and The Danish Heart Foundation, among others.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard